Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

NCT04854083 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Type2 Diabetes

Interventions

DRUG: Semaglutide, 1.34 mg/mL
DRUG: Placebo

Sponsor

Kirsi Pietiläinen

Collaborators

[object Object]
[object Object]